Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
GSK’s consumer spin-off roadshows amid calm after Fed and BofE meetings -
Major shareholder reduces stake in Spanish pharmaceuticals company
-
Saudi Arabia’s IPO market is thriving amid the turmoil caused by Russia’s invasion of Ukraine
-
Boston Scientific plans four tranche deal as European issuers hang back
-
Volatility has become the norm in the US high grade new issue market
-
Swiss market debates whether it has found new limits or cannot support multiple monster trades after biggest deal in 13 years
